AstraZeneca Signs a License Agreement with Redx Pharma for RXC006 to Treat Idiopathic Pulmonary Fibrosis
Shots:
- Redx to receive $17M in early payment by the time of successful commencement of a P-I study- $360M as development- a regulatory and commercial milestone along with royalties on sales of the RXC006
- AstraZeneca to get an exclusive global license to further develop & commercialize RXC006 targeting fibrotic diseases including IPF
- Redx continues to progress its lead oncology asset- RXC004 (porcupine inhibitor) targeting Wnt-driven tumors- currently being evaluated in P-I/II clinical trial- and RXC007- the oral Rock 2 inhibitor targeting fibrosis where first in human studies are expected in 2021
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com